J. A. Szalony

发表

Assessment of Bleeding Propensity in Non-Human Primates by Combination of Selective Tissue Factor/VIIa Inhibition and Aspirin Compared to Warfarin and Aspirin Treatment

M. S. South, J. J. Parlow, A. Salyers, 2004, Pharmacology.

Orbofiban: An orally active GPIIb/IIIa platelet receptor antagonist

R. Anders, A. Salyers, J. A. Szalony, 2001, Medicinal research reviews.

Pharmacological Intervention at Disparate Sites in the Coagulation Cascade: Comparison of Anti-thrombotic Efficacy vs. Bleeding Propensity in a Rat Model of Acute Arterial Thrombosis

T. Girard, J. A. Szalony, N. Nicholson, 2002, Journal of Thrombosis and Thrombolysis.

Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time.

M. S. South, J. J. Parlow, A. Salyers, 2003, Thrombosis research.

Pharmacological Interruption of Acute Thrombus Formation with Minimal Hemorrhagic Complications by a Small Molecule Tissue Factor/Factor VIIa Inhibitor: Comparison to Factor Xa and Thrombin Inhibition in a Nonhuman Primate Thrombosis Model

M. S. South, J. J. Parlow, A. Salyers, 2003, Journal of Pharmacology and Experimental Therapeutics.

Orbofiban: An orally active GPIIb/IIIa platelet receptor antagonist

R. Anders, A. Salyers, J. A. Szalony, 2001, Medicinal research reviews.

Protective effect of oral xemilofiban in arterial thrombosis in dogs: increased activity in combination with aspirin.

L. Feigen, A. Salyers, J. A. Szalony, 1998, Circulation.

Extended inhibition of platelet aggregation with the orally active platelet inhibitor SC-54684A.

D. Mehrotra, L. Feigen, A. Salyers, 1995, Circulation.

Assessment of platelet function assays.

L. Feigen, L P Feigen, D M Lansky, 1998, American heart journal.

SC-54684A: an orally active inhibitor of platelet aggregation.

J. Zablocki, B. Keller, A. Salyers, 1995, Circulation.